ReferencesPackage Insert: http://www.actimmune.com/pdf/ACTIMMUNE_PI_Effective_US%207-16.pdf
1. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991 Feb 21;324(8):509-516. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1846940
2. Key LL, Jr., Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995 Jun 15;332(24):1594-1599. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7753137
3. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9143706
4. Tau G, Rothman P. Biologic functions of the IFN-gamma receptors. Allergy. 1999 Dec;54(12):1233-1251. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10688427
5. The NCCN Drugs and Biologics Compendium (NCCN CompendiumTM) http://www.nccn.org/professionals/drug_compendium/content/contents.asp
6. Richeldi L. Clinical trials of investigational agents for IPF: a review of a Coshrane report. Respir Res. 2013;14 Suppl 1:S4. http://www.ncbi.nlm.nih.gov/pubmed/23734867
7. Seyer L, Greeley N, Foerster D, Strawser C, Gelbard S et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. 2014 Oct 21. http://www.ncbi.nlm.nih.gov/pubmed/25335475
8. Yiu EM, Tai G, Peverill RE, Lee KJ et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015. 262(5):1344-1353. http://www.ncbi.nlm.nih.gov/pubmed/25845763